Journal of pediatric and adolescent gynecology

New Hormone Treatments in Teens: Possible Effects on Growth, Reproduction, and Mental Health

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed to adolescents for obesity and type 2 diabetes mellitus.

  • There is growing interest in using GLP-1 RAs for conditions like polyendocrine metabolic ovarian syndrome (PMOS).
  • Adolescence is a critical period for peak bone mass acquisition.
  • The implications of pharmacologic weight loss during adolescence have received limited attention.
  • Potential concerns include the risk of eating disorders and future reproductive outcomes in adolescents treated with GLP-1 RAs.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

Conflict of Interest and Funding Statements The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. This work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. No external funding was obtained for the preparation of this manuscript.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief